Jump Financial LLC Purchases Shares of 9,769 Vericel Corporation $VCEL

Key Points

• Jump Financial LLC acquired 9,769 shares of Vericel Corporation (NASDAQ:VCEL) valued at approximately $436,000, marking a new position for the institutional investor in the first quarter.
• Vericel reported earnings of ($0.01) per share for the last quarter, beating analysts' expectations and showing a 20.1% year-over-year revenue increase.
• Several analysts have varied opinions on Vericel's stock, with Canaccord Genuity setting a price target of $58.00 and Stephens providing an "overweight" rating with a target of $67.00.

Jump Financial LLC acquired a new stake in shares of Vericel Corporation (NASDAQ:VCEL - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,769 shares of the biotechnology company's stock, valued at approximately $436,000.

Several other institutional investors have also added to or reduced their stakes in VCEL. Stifel Financial Corp raised its position in Vericel by 23.6% during the fourth quarter. Stifel Financial Corp now owns 34,705 shares of the biotechnology company's stock valued at $1,906,000 after purchasing an additional 6,632 shares in the last quarter. Hsbc Holdings PLC acquired a new position in Vericel during the fourth quarter valued at approximately $405,000. Northern Trust Corp raised its position in Vericel by 8.6% during the fourth quarter. Northern Trust Corp now owns 559,442 shares of the biotechnology company's stock valued at $30,719,000 after purchasing an additional 44,397 shares in the last quarter. Captrust Financial Advisors raised its position in Vericel by 3.4% during the fourth quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company's stock valued at $336,000 after purchasing an additional 199 shares in the last quarter. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Vericel during the fourth quarter worth $291,000.

Wall Street Analyst Weigh In

VCEL has been the subject of several research analyst reports. Canaccord Genuity Group lowered their price target on shares of Vericel from $61.00 to $58.00 and set a "buy" rating for the company in a report on Friday, August 1st. Wall Street Zen downgraded shares of Vericel from a "hold" rating to a "sell" rating in a report on Monday, May 12th. Finally, Stephens reiterated an "overweight" rating and set a $67.00 price target on shares of Vericel in a report on Monday, June 16th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $60.40.

Vericel Price Performance

NASDAQ VCEL traded up $0.12 on Thursday, reaching $33.67. The company had a trading volume of 1,129,820 shares, compared to its average volume of 508,588. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 280.61 and a beta of 1.33. Vericel Corporation has a fifty-two week low of $33.09 and a fifty-two week high of $63.00. The business has a 50 day moving average of $37.94 and a two-hundred day moving average of $42.00.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.03. The business had revenue of $63.24 million during the quarter, compared to the consensus estimate of $64.61 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%.Vericel's quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.10) earnings per share. As a group, research analysts predict that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.